Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: Effects of angiotensin II blockade

Journal of Hypertension

Volumn 24, Issue 6, 2006, Pages 1097-1104

  Guo, Peng ^a   Nishiyama, Akira ^a   Rahman, Matlubur ^a   Nagai, Yukiko ^a   Noma, Takahisa ^a   Namba, Tsunetatsu ^a   Ishizawa, Makoto ^a   Murakami, Kazushi ^b   Miyatake, Akira ^a   Kimura, Shoji ^a   Mizushige, Katsufumi ^b   Abe, Youichi ^a   Ohmori, Koji ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Takamatsuhigashi National Hospital   (Japan)

Author keywords

Angiotensin II; Candesartan; Diastolic heart failure; Hypertension; Reactive oxygen species

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; PROTEIN P22; PROTEIN P22PHOX; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM CHLORIDE; TEMPOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; GENE EXPRESSION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE RELAXATION; HEART PROTECTION; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SALT INTAKE;

EID: 33646851569     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000226200.73065.5d     Document Type: Article

References (45)

1. Schmieder RE. Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. J Hypertens 2005; 23:905-911.
2. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21:2251-2257.
3. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Antioxidative effect of p38 mitogen-activated protein kinase inhibitor in the kidney of hypertensive rat. J Hypertens 2005; 23:165-174.
4. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103:148-154.
5. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43:686-691.
6. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000; 47:274-283.
7. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948-1955.
8. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
9. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, et al. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int 2004; 65:972-981.
10. Kobayashi N, Hara K, Higashi T, Matsuoka H. Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats. Am J Hypertens 2000; 13:1088-1096.
11. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 2001; 104:606-612.
12. Nishikimi T, Yoshihara F, Horinaka S, Kobayashi N, Mori Y, Tadokoro K, et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 2003; 42:1034-1041.
13. Inagaki K, Iwanaga Y, Sarai N, Onozawa Y, Takenaka H, Mochly-Rosen D, et al. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. J Mol Cell Cardiol 2002; 34:1377-1385.
14. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22:1141-1149.
15. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000; 91:21-27.
16. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42:1075-1081.
17. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65:245-248.
18. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97:1536-1539.
19. Tsutsui H, Ide T, Hayashidani S, Kinugawa S, Suematsu N, Utsumi H, et al. Effects of ACE inhibition on left ventricular failure and oxidative stress in Dahl salt-sensitive rats. J Cardiovasc Pharmacol 2001; 37:725-733.
20. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, et al. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005; 45:860-866.
21. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, et al. The SOD mimetic tempol ameliorates glomerular injury and reduces MAPK activity in Dahl salt-sensitive rats. J Am Soc Nephrol 2004; 15:306-315.
22. Guo P, Mizushige K, Noma T, Murakami K, Namba T, Ishizawa M, et al. Association of uncoupling protein-2 expression with increased reactive oxygen species in residual myocardium of the enlarged left ventricle after myocardial infarction. Heart Vessels 2005; 20:61-65.
23. Murakami K, Mizushige K, Noma T, Tsuji T, Kimura S, Kohno M. Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts. Hypertension 2002; 40:251-255.
24. Noma T, Nishiyama A, Mizushige K, Murakami K, Tsuji T, Kohno M, et al. Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats. FASEB J 2001; 15:1206-1208.
25. Kimura S, Zhang GX, Nishiyama A, Nagai Y, Nakagawa T, Miyanaka H, et al. D-Allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats. J Hypertens 2005; 23:1887-1894.
26. Hancock JT, Jones OT. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 1987; 242:103-107.
27. Rahman M, Kimura S, Nishiyama A, Hitomi H, Zhang G, Abe Y. Angiotensin II stimulates superoxide production via both angiotensin AT1A and AT1B receptors in mouse aorta and heart. Eur J Pharmacol 2004; 485:243-249.
28. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711.
29. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412.
30. Kimura S, Zhang GX, Nagai Y, Miyata K, Nishiyama A, Shokoji T, et al. Time-dependent transition of tempol-sensitive reduction of blood pressure in angiotensin II-induced hypertension. J Hypertens 2004; 22:2161-2168.
31. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164-2171.
32. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005; 23:1383-1389.
33. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14:1212-1222.
34. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13:2478-2487.
35. Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, et al. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. Free Radic Biol Med 2005; 38:616-630.
36. Zhang L, Fujii S, Igarashi J, Kosaka H. Effects of thiol antioxidanton reduced nicotinamide adenine dinucleotide phosphate oxidase in hypertensive Dahl salt-sensitive rats. Free Radic Biol Med 2004; 37:1813-1820.
37. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003; 42:945-951.
38. Yamamoto K, Mano T, Yoshida J, Sakata Y, Nishikawa N, Nishio M, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23:393-400.
39. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
40. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24:366-378.
41. Sukoyan GV, Karsanov VN, Tatulashvili DR, Gochua EI, Samsonidze TG, Karsanov NV. Subcellular and molecular mechanisms of the effects of cardiac glycosides and angiotensin-converting enzyme inhibitors on contractile function and energy conversion in myocardial myofibrils under normal conditions and during acute cardiac insufficiency. Bull Exp Biol Med 2002; 133:74-80.
42. Porter RK. Mitochondrial proton leak: a role for uncoupling proteins 2 and 3? Biochim Biophys Acta 2001; 1504:120-127.
43. Park JY, Park KG, Kim HJ, Kang HG, Ahn JD, Kim HS, et al. The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells. Diabetologia 2005; 48:1022-1028.
44. Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002; 415:96-99.
45. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.